Breaking News
Get 40% Off 0
🤯 Picked by our AI, this stock rallied more than Nvidia this month, yielding 94% since March See the stock
Close

Merck & Company Inc (MRK)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Merck&Co historical data, for real-time data please try another search
101.40 +0.00    +0.00%
08/06 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  France
ISIN:  US58933Y1055 
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 100.20 - 101.60
Merck&Co 101.40 +0.00 +0.00%

Merck & Co Inc Company Profile

 
Get an in-depth profile of Merck & Company Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

71000

Equity Type

ORD

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Contact Information

Address 126 East Lincoln Avenue
Rahway, 07065
United States
Phone 908 740 4000
Fax -

Top Executives

Name Age Since Title
Christine E. Seidman 69 2020 Independent Director
Patricia F. Russo 70 1995 Independent Director
Inge G. Thulin 68 2018 Independent Director
Peter C. Wendell 71 2003 Independent Director
Stephen L. Mayo 60 2021 Independent Director
Thomas Henry Glocer 63 2007 Independent Lead Director
Paul B. Rothman 64 2015 Independent Director
Pamela J. Craig 65 2015 Independent Director
Mary Ellen Coe 54 2019 Independent Director
Risa J. Lavizzo-Mourey 67 2020 Independent Director
Douglas M. Baker 63 2022 Independent Director
Kathy J. Warden 50 2020 Independent Director
Robert M. Davis 55 2014 CEO & Chairman
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MRK Comments

Write your thoughts about Merck & Co Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
William Hineser
William Hineser Dec 05, 2023 12:58PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I have held this stock since 1995. It have weathered a lot of change and delivered nicely in the long run.
RW Reynolds
RW Reynolds Dec 05, 2023 12:58PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Girlfriend has owned since 1982
Labinot Sojeva
Labinot Sojeva Oct 31, 2023 12:28PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
trash
Brett Govindasamy
Brett Govindasamy Oct 31, 2023 12:28PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
yes you are.
Don Vo
Don Vo Oct 20, 2023 11:37AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
When MS upgrades that a trap
Francesco Sala
Francesco Sala Apr 28, 2023 4:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
it should reach $120 according to the top 12 analysts on TipRanks
William Hineser
William Hineser Apr 27, 2023 11:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Try looking at the big picture. Over time this has been a great investment. Started in 1995 at $22 and has done nothing but make money over the years. stop being short sighted.
Ben Rama
Ben Rama Mar 16, 2023 8:07PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Bearish
Ben Rama
Ben Rama Mar 16, 2023 8:06PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
And why keep it for dividend when uou can get 4-5 percent risk free
Ben Rama
Ben Rama Mar 16, 2023 8:06PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This is hoing down to 80is within months!! Way overpriced and all other smaller players are beating them on new development
William Hineser
William Hineser Feb 09, 2023 10:16AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Ignore small day to day changes. Long term is key.
Jordi Lacchini
Jordi Lacchini Jan 27, 2023 3:53AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
120 loadin
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email